Pharmaceutical

FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

Mar 21, 2025 - 06:00
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.
Read the original article

Tags:

Previous Article

Narrow Field Imager from NRL Debuts on NASA’s PUNCH Mission

Next Article

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Minerva hit with FDA rejection for schizophrenia symptom drug

Minerva hit with FDA rejection for schizophrenia sympto...

Feb 28, 2024

Senator floats new models to manage costs of weight loss drugs like Ozempic

Senator floats new models to manage costs of weight los...

Nov 9, 2023

Breast cancer is deadlier for Black women. A study of mammograms could help close the gap

Breast cancer is deadlier for Black women. A study of m...

Oct 18, 2023